Bioxytran Advances Novel Antiviral to Phase 3, Targeting Multiple Viruses

BOSTON – March 04, 2026 – Clinical-stage biotechnology company Bioxytran, Inc. is advancing its lead antiviral candidate, ProLectin-M, into a pivotal Phase 3 trial following the release of positive dose optimization results. The company is preparing for a 408-patient study intended to support full regulatory approval for treating a range of common respiratory illnesses, including COVID-19, influenza, and RSV. The move marks a significant step for a drug that employs a novel mechanism designed to block viruses from entering host cells, potentially offering a new line of defense against both seasonal infections and future pandemic threats.

Bioxytran announced on March 2 that its recent 39-participant study successfully identified an optimal dosing regimen of 16,800 mg per day. At this dose, ProLectin-M achieved a 90% viral clearance by the fifth day of treatment while maintaining a favorable safety profile. With this critical data in hand, the company has initiated regulatory discussions with the U.S. Food and Drug Administration (FDA) and India’s Central Drugs Standard Control Organization (CDSCO) to finalize the design of its upcoming registrational trial.

A New Strategy in the Antiviral Arsenal

ProLectin-M distinguishes itself from many existing antiviral treatments through its unique mechanism of action. Instead of inhibiting viral replication after a cell is already infected, as drugs like Pfizer’s Paxlovid do, ProLectin-M is a galectin antagonist. It works by blocking galectin proteins, particularly galectin-3, which are found on the surface of human cells.

During an infection, many viruses exploit these galectins to latch onto and enter host cells. By binding to these proteins, ProLectin-M effectively creates a barrier that prevents viral attachment. Scientific research supports this host-directed therapy approach, as it targets a component of the host rather than the virus itself. This may make it more difficult for viruses to develop resistance through mutation, a common challenge for other antivirals.

Bioxytran believes this entry-blocking strategy offers several potential advantages, including a reduced risk of the viral rebound phenomenon seen with some treatments and minimal drug-to-drug interactions. Earlier clinical studies have provided encouraging evidence. A Phase 1b/2a trial in patients with mild-to-moderate COVID-19 showed that the 16,800 mg/day dose led to a statistically significant improvement, with 90% of participants achieving non-detectable viral levels by Day 5, compared to just 20% in the placebo group. This ability to accelerate viral clearance could be crucial for reducing transmission and shortening the duration of illness.

Navigating the High-Stakes Path to Market

The planned Phase 3 trial represents the final and most demanding clinical hurdle before Bioxytran can seek market approval. The study is designed as a randomized, placebo-controlled trial enrolling approximately 408 standard-risk outpatients with mild-to-moderate symptoms of COVID-19, influenza, or RSV. The primary goal will be to demonstrate a statistically significant rate of viral clearance or clinical improvement by Day 5 compared to a placebo.

Successfully conducting a trial of this scale is a formidable undertaking, particularly for a clinical-stage company trading on the OTCQB market. Phase 3 trials are notoriously expensive, often costing tens or even hundreds of millions of dollars, and require complex logistical coordination across multiple clinical sites. Securing adequate funding will be a critical challenge for Bioxytran as it moves forward.

Furthermore, the regulatory pathway for a drug with a novel mechanism of action requires extensive data and rigorous review. Engaging with both the FDA and India’s CDSCO simultaneously indicates a global strategy, but also adds complexity. Regulatory experts note that while agencies are open to innovative therapies, they demand a high bar for evidence demonstrating both safety and a clear benefit over existing standards of care. The success of these regulatory discussions will be crucial in defining the trial's final design and, ultimately, its chances of success.

A Broad-Spectrum Platform for Public Health

Bioxytran’s ambitions for its galectin antagonist platform extend well beyond COVID-19. The company is positioning its technology as a broad-spectrum solution capable of addressing a wide range of viral threats, a strategy that has gained significant attention in a post-pandemic world.

One of the most notable initiatives is a new research collaboration with the University of Georgia, announced in late February. This partnership will evaluate a related compound, PHM23, against the highly pathogenic H5N1 avian influenza virus. The research is part of a larger effort to find alternatives to the mass culling of poultry, which has devastated flocks and threatens the global food supply. In-vitro studies have already shown the molecule’s potential against similar viruses, and a successful outcome could have major implications for both animal health and pandemic preparedness.

In addition to this, Bioxytran is developing ProLectin-I, an intravenous formulation of the drug, for investigation as a treatment for Long COVID. This line of research is based on the theory that persistent viral fragments may contribute to the lingering symptoms experienced by millions. The company has also reported positive in-vitro results showing viral load reduction against H1N1 influenza and RSV, reinforcing the drug's potential as a multi-purpose antiviral.

As Bioxytran prepares to launch its pivotal trial, the company stands at a critical juncture. With promising clinical data and a differentiated scientific approach, it has laid the groundwork for what could be a new class of antiviral therapy. The coming months will be a test of its ability to execute its ambitious clinical plan and navigate the financial and regulatory landscape. If successful, ProLectin-M could offer a powerful new tool to combat the respiratory viruses that sicken millions each year and better prepare the world for the infectious disease threats of tomorrow.